SLC5A2 and hydrops fetalis: SGLT2 was associated with a significant reduction in CV death or HHF,(HR = 0.78, 95% CI: 0.69, 0.87; I2 = 0%); SGLT2 was associated with a significant reduction in HHF (HR = 0.71, 95% CI: 0.61, 0.84; I2 = 0%); No significant differences between SGLT2 and placebo on HF patients in terms of CV death (HR = 1.01, 95% CI: 0.80, 1.28; I2= 23%); No significant differences between SGLT2 and placebo on HF patients in terms all-cause mortality(HR = 1.01, 95% CI: 0.89, 1.14; I2 = 0%)